聯邦制藥(03933.HK)與浙江普洛簽訂合作框架協議
格隆匯7月27日丨聯邦制藥(03933.HK)公佈,公司全資附屬公司聯邦制藥(內蒙古)有限公司("聯邦制藥(內蒙古)")與浙江普洛生物科技有限公司("浙江普洛")共同簽署了關於獸用藥合作框架協議。根據合作框架協議,聯邦制藥(內蒙古)與浙江普洛將以現金方式出資成立經營性合資公司("合資公司"),註冊資金為人民幣 3 億元,聯邦制藥(內蒙古)將持有合資公司 49%股權。
浙江普洛是一家專業從事發酵類原料藥研究、開發、生產的生物製藥企業。浙江普洛系深圳交易所上市公司普洛藥業股份有限公司(股份代號:SZ000739)的全資子公司。
鑑於聯邦制藥(內蒙古)所具備的資源優勢及已建立的企業公共資源規模優勢,以及浙江普洛在生物發酵獸用抗生素領域積累的市場資源和技術競爭力,雙方將充分發揮各自優勢,開展獸藥領域戰略合作,爭取在獸藥領域建立技術、生產與市場全方位的競爭力。合資公司前期合作項目涉及四個獸用抗生素產品。產品的生產管理由雙方各自負責,產品營銷由浙江普洛委派於合資公司的團隊負責。
是次合作為基於雙方優勢及多年合作信任基礎上所達成的,旨在通過發揮雙方技術、市場及其他資源優勢,進一步加強相關獸藥產品市場主導地位,共同推進獸藥領域業務協同發展。
雙方後續將有關合資公司簽訂正式協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.